This offers several potential benefits: Avoids first-pass metabolism : Unlike swallowed medications that must pass through the liver, sublingual absorption delivers drugs directly to the bloodstream Bypasses stomach acid : GLP-1 peptides are degraded by digestive enzymes, so avoiding the stomach could improve stability Rich vascular network : The area under the tongue has extensive blood vessels that allow rapid absorption However, research on peptide delivery through oral mucosa reveals significant challenges: Peptides like semaglutide and tirzepatide have molecular weights around 4000 Da (compounds above 500 Da generally show poor permeability) Salivary and mucosal proteases degrade peptides before they can cross the epithelial barrier Continuous saliva production dilutes and washes away the medication Studies with insulin showed only 1-2% bioavailability via buccal/sublingual routes without absorption enhancers The key question: Do compounded ODT formulations overcome these barriers

Novo Nordisk NVO Fair Value Estimate: $86.00 Morningstar Rating: 2 stars Morningstar Economic Moat Rating: Wide Morningstar Uncertainty Rating: High Novo Nordisk reported constant currency sales growth of 24% in the first quarter, in line with the 25% constant currency sales growth assumption we had built into our model for 2024
- Sn phm ny l thun chay, khng bin i gen v khng cha gluten
Alberta Blue Cross's 2026 drug pipeline report says GLP-1 receptor agonists remain a major cost driver for private plans and that overall GLP-1 therapy plan spend is unlikely to decline in future years, even as a semaglutide generic is expected in mid-2026
It is FDA-approved under three brand names: Wegovy (for weight loss), Ozempic (for type 2 diabetes) and Rybelsus (an oral form for diabetes)